Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04880434 · ClinicalTrials.gov registry record · Phase 2
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
A Phase 2 study of Relapsed/Refractory Mantle Cell Lymphoma, sponsored by Kite, A Gilead Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
- 20
- Study locations
NCT04880434 is a Phase 2 study of Relapsed/Refractory Mantle Cell Lymphoma that has completed, run by Kite, A Gilead Company. The registered enrollment target is 95 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT04880434, a Phase 2 study of Relapsed/Refractory Mantle Cell Lymphoma, has completed, sponsored by Kite, A Gilead Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical study is to test how well the study drug, brexucabtagene autoleucel (KTE-X19), works in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL Brexucabtagene autoleucel
Study Locations (20)
Illinois
- University of Chicago - Chicago
- Loyola University Medical Center - Maywood
- Advocate Aurora Health - Advocate Lutheran General Hospital - Park Ridge
California
- Stanford University - Palo Alto
- University California Los Angeles (UCLA) - Santa Monica
Florida
- University of Miami - Miami
- Moffitt Cancer Center - Tampa
Ohio
- Cleveland Clinic - Taussig Cancer Institute - Cleveland
- Ohio State University - Columbus
Tennessee
- Sarah Cannon - Tenessee - Nashville
- Vanderbilt University - Nashville
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Colorado
- Sarah Cannon- Denver - Denver
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2021-04-27 |
| Est. Completion | 2025-06-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04880434
The ClinicalTrials.gov registry entry for NCT04880434 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Mantle Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT04880434 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Illinois, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04880434 about?
NCT04880434 is a clinical study titled "Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)". The goal of this clinical study is to test how well the study drug, brexucabtagene autoleucel (KTE-X19), works in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL).
What is the current status of trial NCT04880434?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2021-04-27. Estimated completion is 2025-06-17.
What conditions does trial NCT04880434 study?
This clinical trial studies the following conditions: Relapsed/Refractory Mantle Cell Lymphoma.
What interventions are being tested in trial NCT04880434?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Brexucabtagene autoleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT04880434?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04880434 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.